Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued to clients and investors on Thursday. The firm set a “sell” rating on the stock.

A number of other equities analysts also recently commented on SYRS. Brookline Capital Management restated a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. JMP Securities reaffirmed a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright reissued a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Price Performance

Shares of Syros Pharmaceuticals stock opened at $0.24 on Thursday. The stock has a market cap of $6.39 million, a price-to-earnings ratio of -0.08 and a beta of 1.31. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25. The stock has a 50 day moving average price of $0.44 and a 200-day moving average price of $2.21. Syros Pharmaceuticals has a one year low of $0.18 and a one year high of $7.96.

Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same period in the previous year, the company earned ($1.35) earnings per share. Equities analysts expect that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insiders Place Their Bets

In related news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the transaction, the director now owns 41,070 shares in the company, valued at $11,088.90. The trade was a 76.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 12.26% of the stock is owned by company insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of SYRS. Acadian Asset Management LLC grew its stake in shares of Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock worth $178,000 after acquiring an additional 17,416 shares during the last quarter. Exome Asset Management LLC boosted its stake in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock worth $642,000 after purchasing an additional 139,400 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Syros Pharmaceuticals during the third quarter valued at $34,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.